Physician profile
Brian Eugene Hancock
NPI 1720088693
$1,773.39
in general payments reported to CMS, 2019-2025
15 companies · $329 in 2025
The $329 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $192 · 2020: $151 · 2021: $246 · 2022: $90.21 · 2023: $349 · 2024: $416 · 2025: $329.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,095.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,094.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $877.39 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Janssen Pharmaceuticals, INC | $270.67 | 2019-2023 | Xarelto |
| Lilly USA, LLC | $138.86 | 2019-2024 | Mounjaro |
| Abbvie INC. | $98.92 | 2021-2025 | |
| Astellas Pharma US INC | $89.00 | 2021 | |
| Novo Nordisk INC | $56.77 | 2020-2024 | Rybelsus, Ozempic |
| Pfizer INC. | $46.75 | 2019-2024 | |
| Medtronic, INC. | $35.67 | 2023 | Venaseal |
| Amgen INC. | $31.73 | 2020-2021 | |
| Glaxosmithkline, LLC. | $28.37 | 2025 | Trelegy Ellipta |
| Novartis Pharmaceuticals Corporation | $23.48 | 2019 | |
| Esperion Therapeutics, INC. | $21.45 | 2020 | |
| Exact Sciences Corporation | $20.17 | 2025 | The Cologuard Plus Collection Kit |
| Allergan, INC. | $18.35 | 2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $15.81 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Hancock listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.